<div>
  <ul>
    <li>
      <p>
        Core One Labs Inc., a biotech research and development firm specialized in psychedelic medicine, has announced a non-brokered private placement to raise up to CAD 1.5 million (USD 1.1 million). The placement consists of units priced at CAD 0.15 each (USD 0.11). Each unit will comprise one share and half of a transferable share purchase warrant. Each whole warrant will entitle the holder to purchase one additional share at a price of CAD 0.20 (USD 0.15) within five years from its issuance. The first tranche of the placement is scheduled to close on April 17, 2024.
      </p>
    </li>
    <li>
      <p>
        The proceeds from the placement are expected to be used for working capital and for general corporate tasks, aimed at boosting the business processes.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.marketscreener.com/quote/stock/CORE-ONE-LABS-INC-65218786/news/Core-One-Labs-Announces-Non-Brokered-Private-Placement-46399650/">
      Market Screener
    </a>
  </p>
</div>


Psychedelic Medicine

<div>
 <p>Core One Labs Inc., a company specializing in psychedelic medicine research and development, has declared a non-brokered private placement intending to acquire up to CAD 1.5 million (USD 1.1 million). This placement comprises units, each valued at CAD 0.15 (USD 0.11), consisting of one share and a half share purchase warrant, transferable. Entire warrants give holders the ability to buy an additional share at CAD 0.20 (USD 0.15) valid for the next five years from the date of issuance. The first part of this placement is set to close on April 17, 2024.</p>
 <p>The capital raised from this placement is projected to be used for working capital and other general corporate purposes, aiming to enhance business processes.</p>
</div>

All Updates

Core One Labs secures CAD 1.5 million via private placement for working capital and general corporate purposes

Core One Labs to explore takeover by big pharma

Core One Labs completes acquisition of Awakened Biosciences

Core One Labs completes acquisition of Frontier Mycology